| AASLD

Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats

Read more about Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats

Lakmie S. Gunarathne, Indu G. Rajapaksha, Stephen Casey, Tawar Qaradakhi, Anthony Zulli, Harinda Rajapaksha, Jonel Trebicka, Peter W. Angus, Chandana B. Herath – 19 May 2022 – Splanchnic vasodilatation contributes to the development and aggravation of portal hypertension (PHT). We previously demonstrated that in cirrhosis, angiotensin‐ mediates splanchnic vasodilatation through the Mas receptor (MasR).

Posttransplant complications in the setting of acute‐on‐chronic liver failure and considerations regarding immunosuppression

Read more about Posttransplant complications in the setting of acute‐on‐chronic liver failure and considerations regarding immunosuppression

M. Valerie Lin, Fredric D. Gordon – 19 May 2022

PRO: Patients With Acute‐on‐Chronic Liver Failure Should Receive Priority on the Liver Transplant Waiting List

Read more about PRO: Patients With Acute‐on‐Chronic Liver Failure Should Receive Priority on the Liver Transplant Waiting List

Rachel H. Westbrook, Elaine L. Burrell, Rajiv Jalan – 19 May 2022

Con: Patients With Acute‐on‐Chronic Liver Failure Should Not Receive Priority on the Waiting List

Read more about Con: Patients With Acute‐on‐Chronic Liver Failure Should Not Receive Priority on the Waiting List

Nadim Mahmud, K. Rajender Reddy – 19 May 2022

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”

Read more about Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”

Laurens A. Kleef, Robert J. Knegt – 19 May 2022

Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus

Read more about Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus

Le Zhang, Shaoying Yang, Yongfu Yu, Suli Wang, Yuetian Yu, Yi Jin, Aimin Zhao, Yimin Mao, Liangjing Lu – 19 May 2022 – The appropriate prophylaxis for hepatitis B virus reactivation (HBVr) during gestation for immunocompromised pregnant women has yet to be determined. The prophylactic efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B surface antigen (HBsAg)–positive patients and the HBVr risk in hepatitis B core antibody (HBcAb)–positive patients during gestation were investigated.